Autologous CAR-T cell therapy expressing the BAFF-ligand. 비교 | 바이오정보모아

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview Toxicology Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 1 Autologous CAR-T cell therapy expressing the BAFF-ligand. (Autologous CAR-T cell therapy expressing the BAFF-ligand.) Luminary Therapeutics·FRα 1 trials

Overview Program	Autologous CAR-T cell therapy expressing the BAFF-ligand.
Overview Company	Luminary Therapeutics
Overview Modality	CGT
Overview Target	FRα
Overview Indication	Multiple Myeloma, Refractory; Multiple Myeloma in Relapse
Overview Phase	PHASE_1
Overview Status	RECRUITING
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

Toxicology Major finding	Cell therapy for a rare disease- hairy cell leukemia variant.. Hairy cell leukemia variant (HCL-v) is a rare malignancy of clonal mature B-cells that follows a chronic disease course. HCL-v patients are often resistant to purine nucleoside analogs, which are the first-line therapy. To address the shortcomings of current therapy for HCL-v, we investigated the activity of a BAFF ligand-based CAR-T c…

Clinical Safety signal	Cell therapy for a rare disease- hairy cell leukemia variant.. Hairy cell leukemia variant (HCL-v) is a rare malignancy of clonal mature B-cells that follows a chronic disease course. HCL-v patients are often resistant to purine nucleoside analogs, which are the first-line therapy. To address the shortcomings of current therapy for HCL-v, we investigated the activity of a BAFF ligand-based CAR-T c…
Clinical Program phase	PHASE_1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview Toxicology Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 1 Autologous CAR-T cell therapy expressing the BAFF-ligand. (Autologous CAR-T cell therapy expressing the BAFF-ligand.) Luminary Therapeutics·FRα 1 trials

Overview Program	Autologous CAR-T cell therapy expressing the BAFF-ligand.
Overview Company	Luminary Therapeutics
Overview Modality	CGT
Overview Target	FRα
Overview Indication	Multiple Myeloma, Refractory; Multiple Myeloma in Relapse
Overview Phase	PHASE_1
Overview Status	RECRUITING
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

Toxicology Major finding	Cell therapy for a rare disease- hairy cell leukemia variant.. Hairy cell leukemia variant (HCL-v) is a rare malignancy of clonal mature B-cells that follows a chronic disease course. HCL-v patients are often resistant to purine nucleoside analogs, which are the first-line therapy. To address the shortcomings of current therapy for HCL-v, we investigated the activity of a BAFF ligand-based CAR-T c…

Clinical Safety signal	Cell therapy for a rare disease- hairy cell leukemia variant.. Hairy cell leukemia variant (HCL-v) is a rare malignancy of clonal mature B-cells that follows a chronic disease course. HCL-v patients are often resistant to purine nucleoside analogs, which are the first-line therapy. To address the shortcomings of current therapy for HCL-v, we investigated the activity of a BAFF ligand-based CAR-T c…
Clinical Program phase	PHASE_1